|
|
|
|
|
|
|
Novabay Pharmaceuticals (NBY)
|
|
3.334 -0.016 (-0.48%)
|
04-20 14:12
|
|
Open:
|
3.34
|
Pre. Close:
|
3.35
|
|
High:
|
3.35
|
Low:
|
3.334
|
|
Volume:
|
1,496
|
Market Cap:
|
57M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
3.355 - 3.372
|
3.372 - 3.386
|
|
Low:
|
3.29 - 3.309
|
3.309 - 3.323
|
|
Close:
|
3.304 - 3.332
|
3.332 - 3.355
|
|
|
|
Technical analysis (as of: 2018-04-20 4:32:04 PM)
|
|
Overall:
|
|
|
Stoxline posted a BUY today, same as yesterday. This stock seems to continue bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, upward move is expected.
|
|
Target:
|
Six months: 4.15 One year: 4.50
|
|
Support:
|
Support1: 3.07 Support2: 2.55
|
|
Resistance:
|
Resistance1:
3.55 Resistance2: 3.85
|
|
Pivot:
|
3.30 
|
|
Moving Averages:
|
MA(5): 3.27  MA(20): 3.34
MA(100): 3.53 MA(250): 3.77
|
|
MACD:
|
MACD(12,26):
-0.04 Signal(12,26,9): -0.04
|
|
%K %D:
|
%K(14,3): 56.53 %D(3): 45.35
|
|
RSI:
|
RSI(14): 50.22
|
|
52-Week:
|
High: 5
Low: 2.25 Change(%): 2.3
|
|
Average Vol(K):
|
3-Month: 732
10-Days 281
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.NBY has closed below upper band by 42.9%. Bollinger Bands are 36.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-03-20T22:54:06-04:00
NovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q4 2017 Results - Earnings Call Transcript
2018-03-20T16:11:54-04:00
NovaBay beats by $0.09, beats on revenue
2018-03-20T16:05:00-04:00
NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results
2018-02-21T06:50:00-05:00
NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018
2018-02-18T05:43:53-05:00
Week In Review: Harbin Pharma Invests $300 Million In U.S.-Based GNC; Forms China JV
2018-02-14T08:00:00-05:00
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
2018-02-12T06:50:00-05:00
NovaBay Pharmaceuticals Completes $6.0 Million Private Placement
2018-02-08T08:00:00-05:00
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
